Dr. Reddy's Laboratories outperforms competitors on strong trading day
Dr. Reddy's Laboratories Ltd. closed 12.96% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
A recombinant anti-CD38 fully human monoclonal antibody injection, HLX15 comes in both intravenous and subcutaneous ...
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories sees a weekly return of 3.53%
Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the ...
money.rediff23h
Dr Reddy's Subsidiary Partners with Henlius for Cancer Drug
Dr Reddy's Laboratories subsidiary signs licence agreement with Shanghai Henlius Biotech for development and ...
Daily2h
Dr Reddy's Labs inks pact with Henlius for commercialization of multiple myeloma injection HLX15 in US, Europe
Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...
Dr Reddy’s arm ties up with Shanghai Henlius Biotech
Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius Biotech, Inc to develop and commercialise an under-development cancer drug. Dr Reddy’s ...
Dr. Reddy’s, Shanghai Henlius Biotech ink $131.6 million cancer drug deal
Dr. Reddy’s to develop and commercialize biosimilar candidate for Johnson & Johnson’s Darzalex drugs with Shanghai Henlius Biotech.
Pharmabiz22h
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...
devdiscourse23h
Dr Reddy's and Shanghai Henlius Join Forces for Cancer Breakthrough
Dr Reddy’s Laboratories has signed a license deal with Shanghai Henlius Biotech to develop and market HLX15, an investigational cancer drug. Henlius will handle development and manufacturing, ...